Related Experiment Video

Updated: Nov 10, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.7K

Development of a Cancer Vaccine Using In Vivo Click-Chemistry-Mediated Active Lymph Node Accumulation for Improved

Hao Qin1,2, Ruifang Zhao1,2,3, Yuting Qin1,2

  • 1CAS Key Laboratory for Biological Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, China, Beijing, 100190, China.

Advanced Materials (Deerfield Beach, Fla.)
|April 1, 2021
PubMed

Insights

This study introduces an active lymph node accumulation system (ALAS) for cancer vaccines. ALAS significantly enhances therapeutic effects and survival rates by improving vaccine delivery to lymph nodes.

Area of Science:

  • Immunology
  • Biotechnology
  • Oncology

Background:

  • Cancer vaccines offer a promising therapeutic strategy due to potent immune responses and low toxicity.
  • Improving in vivo efficacy of cancer vaccines is crucial, with direct lymph node targeting showing significant potential.

Purpose of the Study:

  • To develop a novel active lymph node accumulation system (ALAS) for enhanced cancer vaccine delivery.
  • To improve the delivery of encapsulated antigen and adjuvant to lymph nodes using click chemistry.

Main Methods:

  • Surface modification of lymphatic endothelial cells with azide groups to create targets.
  • Utilizing dibenzocyclooctyne (DBCO)-modified liposomes for targeted delivery.
  • Formulating vaccines with OVA257-264 peptide and poly(I:C) loaded into liposomes.

Main Results:

  • The ALAS approach successfully targeted liposomes to lymph nodes.
  • Vaccines formulated with ALAS elicited a significantly enhanced CD8+ T cell response in vivo.
  • ALAS-treated mice showed a 100% improvement in survival over 60 days compared to controls.

Conclusions:

  • The novel ALAS approach is a powerful strategy for delivering vaccine components to lymph nodes.
  • Targeted delivery to lymph nodes via ALAS enhances antitumor immunity.
  • This system holds promise for improving the efficacy of cancer vaccines.
Keywords:
cancer vaccinesclick chemistryimmunotherapylymph node targeting

More Related Videos

Intra-lymph Node Injection of Biodegradable Polymer Particles09:06

Intra-lymph Node Injection of Biodegradable Polymer Particles

Published on: January 2, 2014

14.8K
Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

1.0K

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
607
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
818